2024 World Conference on Lung Cancer (WCLC) - Posters-P1.13A.10 Efficacy and Safety of Lurbinectedin for Small Cell Lung Cancer in a Real-World Setting: Jazz EMERGE 402 Study

P1.13A.10 Efficacy and Safety of Lurbinectedin for Small Cell Lung Cancer in a Real-World Setting: Jazz EMERGE 402 Study

Back to course

Pdf Summary

The Jazz EMERGE 402 study assesses the real-world effectiveness and safety of lurbinectedin in patients with extensive-stage small cell lung cancer (ES-SCLC) progressing after initial chemotherapy. Lurbinectedin had previously received accelerated FDA approval based on a phase 2 trial showing a 35.2% overall response rate (ORR) and a median response duration of 5.3 months. The current study evaluates a broader ES-SCLC patient population, integrating those with worse prognostic indicators often underrepresented in clinical trials, such as older age and CNS involvement.<br /><br />The preliminary findings reveal that lurbinectedin continues to show clinical benefits in real-world settings, with effectiveness outcomes like ORR and progression-free survival (PFS) comparable to previous studies. Specifically, second-line (2L) therapy recipients generally showed better response rates and disease control than third-line (3L) therapy patients. Notably, the study found no new safety concerns; the adverse events were consistent with prior studies, indicating manageable and tolerable situations for most patients.<br /><br />Key outcomes demonstrated a median overall survival (OS) of 7.6 months in 2L therapy patients, affirming previous observational outcomes. Despite the inclusion of patients with challenging prognostic factors, the positive results bolster the efficacy and safety profile of lurbinectedin. The study underscores its applicability in a diverse patient demographic beyond strictly controlled clinical trials, potentially offering a viable treatment option for those with advanced SCLC stages.<br /><br />Continued observation and data collection in Jazz EMERGE 402 will aim to provide comprehensive insights into the long-term outcomes and optimize treatment protocols, contributing valuable real-world evidence to support lurbinectedin’s utilization in daily oncological practice.

Asset Subtitle

Balazs Halmos

Meta Tag

Speaker Balazs Halmos

Topic SCLC & Neuroendocrine Tumors

Keywords

Jazz EMERGE 402

lurbinectedin

extensive-stage small cell lung cancer

real-world effectiveness

safety

overall response rate

progression-free survival

median overall survival

second-line therapy

adverse events